Sputum Studies of Anti-Citrullinated Protein Antibodies (ACPA) and Rheumatoid Arthritis (RA) Origins — SPARO  

Rheumatoid Arthritis Clinical Trial

Official title: Sputum Studies of Anti-Citrullinated Protein Antibodies (ACPA) and Rheumatoid Arthritis (RA) Origins

Status Recruiting

Clinical Trial Summary

The study is designed to learn more about the causes of rheumatoid arthritis (RA). People who get RA have elevated protein markers called autoantibodies in their blood years before initial symptoms of arthritis. The goal of this study is to learn more about how autoantibodies in RA might be related to inflammation in the lungs.

Clinical Trial Description

The Specific Aims of This Study Are As Follows:

1. Identify whether sputum anti-CCP predicts incident RA

2. Determine the effect of inflammatory cytokines on the induction of NETosis in sputum neutrophils

3. Determine the role of sputum macrophage phagocytosis in NET clearance <br> The knowledge gained from this study will improve the overall understanding of the development of RA. It is anticipated that these findings will improve the field's understanding of how best to screen for RA risk and target RA prevention. This study could support future lung-targeted prevention strategies for RA that could avoid the administration of systemic toxic therapies. Such potential prevention interventions could be implemented in subjects at risk for RA in order to prevent the irreversible joint damage that can occur in the later stages of clinically-apparent RA. ;

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Rheumatoid Arthritis

• NCT number: NCT04474392
• Study type: Observational
• Source: University of Colorado, Denver
• Contact: Kasey Bales
• Phone: 303-724-0071
• Email: KASEY.BALES@CUANSCHUTZ.EDU
• Status: Recruiting
• Start date: August 1, 2020
• Completion date: July 14, 2025